Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma

Toxicology and Applied Pharmacology 232 (2008) 203–209

Contents lists available at ScienceDirect

Toxicology and Applied Pharmacology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y t a a p

Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma Chi-Jung Chung a, Chi-Jung Huang a, Yeong-Shiau Pu b, Chien-Tien Su c, Yung-Kai Huang d, Ying-Ting Chen d, Yu-Mei Hsueh e,⁎ a

Graduate Institute of Public Health, Taipei Medical University, Taipei, Taiwan Department of Urology, National Taiwan University Hospital, Taipei, Taiwan Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan d Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan e Department of Public Health, School of Medicine, Taipei Medical University, No. 250 Wu-Hsing Street, Taipei 110, Taiwan b c

a r t i c l e

i n f o

Article history: Received 11 April 2008 Revised 10 June 2008 Accepted 21 June 2008 Available online 1 July 2008 Keywords: Urothelial carcinoma 8-hydroxydeoxyguanine Urinary arsenic profile Cell cycle p53 p21 CCND1 Polymorphism

a b s t r a c t Introduction: Polymorphisms in p53, p21 and CCND1 could regulate the progression of the cell cycle and might increase the susceptibility to inorganic arsenic-related cancer risk. The goal of our study was to evaluate the roles of cell cycle regulatory gene polymorphisms in the carcinogenesis of arsenic-related urothelial carcinoma (UC). Methods: A hospital-based case-controlled study was conducted to explore the relationships among the urinary arsenic profile, 8-hydroxydeoxyguanosine (8-OHdG) levels, p53 codon 72, p21 codon 31 and CCND1 G870A polymorphisms and UC risk. The urinary arsenic profile was determined using high-performance liquid chromatography (HPLC) and hydride generator-atomic absorption spectrometry (HG-AAS). 8-OHdG levels were measured by high-sensitivity enzyme-linked immunosorbent assay (ELISA) kits. Genotyping was conducted using polymerase chain reaction-restriction fragment length polymerase (PCR-RFLP). Results: Subjects carrying the p21 Arg/Arg genotype had an increased UC risk (age and gender adjusted OR = 1.53; 95% CI, 1.02–2.29). However, there was no association of p53 or CCND1 polymorphisms with UC risk. Significant effects were observed in terms of a combination of the three gene polymorphisms and a cumulative exposure of cigarette smoking, along with the urinary arsenic profile on the UC risk. The higher total arsenic concentration, monomethylarsonic acid percentage (MMA%) and lower dimethylarsinic acid percentage (DMA%), possessed greater gene variant numbers, had a higher UC risk and revealed significant dose–response relationships. However, effects of urinary 8-OHdG levels combined with three gene polymorphisms did not seem to be important for UC risk. Conclusions: The results showed that the variant genotype of p21 might be a predictor of inorganic arsenicrelated UC risk. © 2008 Elsevier Inc. All rights reserved.

Introduction Bladder cancer is the most common malignancy of the urinary tract and the ninth most common cancer in Taiwan. It was estimated that 1858 new cases would be diagnosed and 634 deaths would occur in Taiwan in 2003 (Department of Health, the Executive Yuan, 2007). Tobacco smoking, the most important risk factor for bladder cancer, accounted for ∼ 50% of all cases. In our previous studies (Pu et al., 2007) we found that there was an approximately two-fold higher risk of urothelial carcinoma (UC) risk in smokers than in non-smokers.

⁎ Corresponding author. Fax: +886 2 27384831. E-mail address: [email protected] (Y.-M. Hsueh). 0041-008X/$ – see front matter © 2008 Elsevier Inc. All rights reserved. doi:10.1016/j.taap.2008.06.011

Furthermore, smoking and the urinary arsenic profile were found to be related factors affecting the UC risk. Inorganic arsenic is recognized as a potent human carcinogen. Epidemiological studies of the carcinogenicity of inorganic arsenic have been demonstrated dose–response relationships between inorganic arsenic exposure and cancers of the skin, lung, bladder, liver and kidney among inorganic arsenic-exposed populations (Bates et al., 1992; Tapio and Grosche, 2006; Yoshida et al., 2004). The carcinogenic mechanism underlying the effects of inorganic arsenic remains unclear although putative carcinogenic modes of action have recently been proposed, implicating chromosome abnormalities, oxidative stress, altered growth factors and DNA repair as well as cell proliferation (Kitchin, 2001). Recently, we have shown that subjects who had higher MMA% and/or lower DMA% had an increased UC risk, even at low exposure levels (Pu et al., 2007). In

204

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209

addition, urinary arsenic profile was found to be associated with oxidative DNA damage by using measurements of 8-OHdG levels (Chung et al., 2008). It is therefore worthwhile to examine the mechanisms underlying the ability of inorganic arsenic to induce UC. It is a well known that inorganic arsenic can cause DNA damage, as well as inhibiting the DNA repair pathway and this may cause genomic instability (Gonsebatt et al., 1992; Hartwig et al., 2003). The tumor suppressor protein p53 plays a major role in the control of cell growth and maintenance of genomic stability (De et al., 2006). The codon 72 Arg/Pro polymorphism of p53 that changes an arginine (Arg) to a proline (Pro), due to a G to C transversion was the first to be described (Sun et al., 1999). Missense mutations of the p53 gene marks changes in the structure of the p53 protein and were found to be among the most common genetic alterations in human disease or that led to cancer susceptibility (Furihata et al., 2002). Several studies on breast and bladder cancer have examined the relationship between p53 codon 72 polymorphism and various malignancies, although with conflicting results (Kuroda et al., 2003; Papadakis et al., 2000; Sjalander et al., 1996; Soulitzis et al., 2002). Cell proliferation depends on an ordered and tightly regulated process known as the cell cycle, which is regulated by complexes composed of regulatory cyclins and catalytic cyclin-dependent kinases (CDKs) (Hernandez-Zavala et al., 2005). p21, also known as CIP1/WAF1, is a cyclin kinase inhibitor that acts as a negative regulator of the cell cycle by suppressing the activity of CDKs (Cai and Dynlacht, 1998) and acts as a downstream mediator of p53 tumor suppression (Xiong et al., 1993). The p21 gene has a p53 transcriptional regulatory motif, and cells lacking functional p53 express very low levels of p21, suggesting that p53 directly regulates p21 expression (Gumerlock et al., 1997). Cyclin D1, an intracellular cell-cycle regulatory protein with checkpoint function, plays an important role in the transition from the G1 to S phase of the cell cycle and can promote cell proliferation, or induce growth arrest and apoptosis, depending on the cellular context (Ceschi et al., 2005; Yu et al., 2003). Several polymorphisms in the p21 and CCND1 gene loci have been described. A polymorphism in the p21 codon 31 has been found which produces a C-to-A change, causing a substitution from serine (Ser) to arginine (Arg) (Mousses et al., 1995). This polymorphism probably encodes for a DNA-binding zincfinger domain, causing functional changes to the p21 protein (Ressiniotis et al., 2005). Gene alterations of p21 might be able to interrupt the p53-mediated pathway of cell cycle arrest and increase the susceptibility for cancer (Mousses et al., 1995). A series of epidemiological studies found that p21 codon 31 polymorphism was associated with increased risks of lung, cervical, breast, esophageal, and nasopharyngeal cancers (Keshava et al., 2002; Roh et al., 2001; Tsai et al., 2002; Sjalander et al., 1996), although conflicting findings have been reported (Su et al., 2003; Sun et al., 1995). The gene encoding cyclin D1, CCND1, has a common G870A polymorphism at codon 242 in exon 4 that increases the frequency of alternate splicing, leading to an altered protein (Betticher et al., 1995). Several association studies show the CCND1 870AA genotype to be at an increased risk for several malignancies, including for example in the upper aero-digestive tract, larynx and colon (Izzo et al., 2003; Yu et al., 2003). To our knowledge, no study has simultaneously examined the effect of three polymorphisms in cell cycle regulatory genes on UC risk. Furthermore, the hypothesis that inorganic arsenic-related UC risk is associated with polymorphisms of cell cycle regulatory genes under higher oxidative stress was tested. Materials and methods Study participants. We conducted a hospital-based case-controlled study. The Study design has been described previously (Chung et al.,

2008). Briefly, from September 2002 to April 2006, we recruited 170 UC cases and 402 healthy control participants from the Medical Center that includes National Taiwan University Hospital and Taipei Municipal Wan Fang Hospital. All UC cases were diagnosed by histological confirmation. Healthy controls were frequency matched to UC cases in terms of age, ± 5 years, as well as gender and had no prior history of cancer. All study participants mostly came from Taipei city (N80%) and drank tap water. The average arsenic concentration of tap water is 0.7 μg/L (ranging from undetectable to 4.0 μg/L), according to the Taipei Water Department of the Taipei City Government. Informed consent forms were provided by all participants before a questionnaire interview and collection of biological specimens. The Research Ethics Committee of the National Taiwan University Hospital, Taipei, Taiwan, approved the study and it was consistent with the World Medical Association Declaration of Helsinki. Questionnaire interview and biological specimen collection. Trained interviewers collected information through a face-to-face interview based on a structured questionnaire. The context of the questionnaire included demographics and socioeconomic characteristics, lifestylerelated risk factors for UC risk, such as cigarette smoking and alcohol, tea and coffee consumption, also hair dye use, as well as personal and family histories of disease. Spot urine samples were collected at the time of recruitment in the afternoon and immediately transferred to a −20 °C freezer until required for urinary arsenic species and 8-OHdG levels analyses. At the same time, blood specimens were collected and frozen at −80 °C for DNA extraction. All UC cases had not yet received any treatment before urine and blood collection. Urinary arsenic species and 8-OHdG assessment. Urinary arsenic species, including arsenite (iAs3+), arsenate (iAs5+), MMA5+ and DMA5+ were measured by high-performance liquid chromatography (HPLC), equipped with a hydride generator and atomic absorption spectrometer (HG-AAS), as previously described (Hsueh et al., 1998). Ranges for iAs3+, DMA5+, MMA5+, and iAs5+ recovery rates were from 93.8% to 102.2%, with detection limits of 0.02, 0.08, 0.05, and 0.07 μg/L, respectively. Urinary 8-OHdG measurement was analyzed with a competitive enzyme-linked immunosorbent assay (ELISA) kit in vitro (Japan Institute for the Control of Aging, Fukuroi, Japan), as described in detail elsewhere (Chung et al., 2008). The detection range of the ELISA assay was 0.5–200 ng/mL. The intra- and inter assay coefficient of variance (CV) was 9.8% and 6.7%, respectively. Chen et al. (2002b) have shown that urinary arsenic species are stable for at least 6 months when preserved at −20 °C (Chen et al., 2002b). A good reproducibility (r = 0.96) of measured 8-OHdG concentrations was found when consecutive series of determination within 2 days or 6 months were compared when preserved at −20 °C (Pilger et al., 2002). Hence, the urine sample assay of arsenic species and 8-OHdG levels were therefore performed within 6 months post-collection. Genotyping. Genomic DNA for analysis was extracted from blood specimens using proteinase K digestion following phenol and chloroform extraction. Genotyping for single nucleotide polymorphisms (SNPs) in p53, p21 and CCND1 was carried out for all participants by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique (Ara et al., 1990; Le et al., 2003; Li et al., 1995). Briefly, the primers 5′-TTGCCGTCCCAAGCAATGGATGA-3′ (forward) and 5′-TCTGGGAAGGGACAGAAGATGAC-3′ (backward) for p53 Arg72Pro polymorphism, 5′-GTCAGAACCGGCTGGGGATG-3′ and 5′-CTCCTCCCAACTCATCCCGG-3′ for p21 Ser31Arg polymorphism as well as 5′-AGTTCATTTCCAATCCGCCC-3′ and 5′-TTTCCGTGGCACTAGGTGTC-3′ for CCND1 G870A polymorphism were used to amplify 199 bp, 272 bp and 212 bp PCR products, respectively. PCR

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209

products were obtained in a total volume of 30 μL, consisting of an 80 ng sample DNA, 10× PCR buffer, 2.5 mM dNTP, 2 μM of each primer and 2 U Taq polymerase. After initial denaturation for 5 min at 94 °C, 35 cycles were performed at 94 °C, 30 s (denaturation), at 55°C, 1 min (annealing) and at 72 °C, 1 min (extension) for p53, 94 °C, 40 s, at 61 °C, 30 s and at 72 °C, 40 s for p21, and 94 °C, 30 s, at 60 °C, 30 s and at 72 °C, 30 s for CCND1 followed by a final step for 5 min at 72 °C. The amplified products were visualized by electrophoresis in a 2% agarose gel. PCR products were digested with BstUI (N12 h, at 60 °C) for p53, BlpI (5 h, at 37°C) for p21 and MspI (2 h, at 37 °C) for CCND1. Genotypes were analyzed by electrophoresis on 3% agarose gels. For quality control, a random 5% of the samples were repeated with a concordance of 100%. Statistical analysis. Urine arsenic profile included total arsenic concentration, InAs%, MMA% and DMA%. The total arsenic concentration (μg/g creatinine) was determined by the sum of iAs3+, iAs5+, MMA5+ and DMA5+. The relative proportion of each arsenic species (InAs%, MMA% and DMA%) was calculated by dividing the concentration of each species by the total arsenic concentration. A Log10-transformation was applied to the 8-OHdG levels and urinary arsenic profile with an abnormal distribution before statistical analyses being performed. The frequency distribution of the polymorphisms was tested in the control group to ensure a Hardy– Weinberg equilibrium. Also we performed a multivariate logistic regression analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs), to evaluate the impact of relevant variables (cumulative exposure of cigarette smoking, urinary arsenic profile, 8-OHdG levels and related polymorphisms) on UC risk, after adjustment for other confounders. Tertile values of urinary arsenic profile and 8-OHdG levels of the controls were used as a cutoff for trend test. Also, median value of cumulative exposure of cigarette smoking was used as a cutoff except 0. For dose–response relationships, trend analysis was performed by treating ordinal-score variables as continuous variables in the logistic regression model. In our previous work, we described the UC-related risk factors, including education, paternal and maternal ethnicity, alcohol drinking and pesticide usage (Pu et al., 2007), so we adjusted for these variables in the final multivariate logistic regression. In addition to adjusting above variables, we considered the collinearity between total arsenic concentration and different urinary arsenic profile. Then, we chose proper adjustment in final models for different urinary arsenic profile. All data analyses were performed out using the SAS statistical package (SAS, version 8.0, Cary, NC). Results Subjects who had higher educational levels had a lower risk UC than those with lower educational levels. Mainland Chinese had a significantly lower UC risk than the Fukien Taiwanese. Age, ABO blood type, marital status or use of hair dye did not affect the UC risk. Occasional alcohol drinkers had a significantly lower UC risk than non-drinkers and frequent drinkers. Pesticide users had a significantly higher UC risk than non-users in this study, as described in our previous work (Pu et al., 2007). Age, gender, urinary 8-OHdG levels and p53, p21 and CCND1 genotype frequency data are shown in Table 1. The urinary 8-OHdG levels in 170 UC patients were significantly higher than in the 402 controls (p = 0.03 for Student’s t-test). After adjusting for age and gender, a significantly elevated risk of UC with increasing urinary 8-OHdG levels (per unit) was found. However, a significant dose–response relationship between urinary 8-OHdG levels and UC risk was not observed. In controls, genotype distributions of p53 codon 72, p21 codon 31 and CCND1 G870A were fitted in Hardy–Weinberg equilibrium. For the p21 codon 31 polymorphism, the number of cases (n = 51) that were carrying 30.18% of the variant homozygote

205

genotype (Arg/Arg) was higher than that of the controls at 22.14% (n = 89). Subjects carrying the Arg/Arg genotype had a significantly increased risk of UC (OR = 1.53; 95% CI, 1.02–2.29), compared to those carrying Ser/Ser or Ser/Arg genotypes, after adjustment for age and gender. However, we did not detect a significant association between the p53 or CCND1 genotype and UC risk, neither in a dominant, nor in a recessive model. The median ± standard error of urinary arsenic species, cumulative exposure of cigarette smoking and 8-OHdG levels is similar among three genotype groups in p53, p21 and CCND1 (data not shown). Multivariateadjusted ORs for the combination of the effects of the environmental exposure and p53, p21 and CCND1 polymorphisms on the UC risk are shown in Table 2. For p53 polymorphism, those who had at least one variant allele and the highest level group of cumulative exposure of cigarette smoking, total arsenic concentration, InAs%, and MMA% and the group with lower levels of DMA%, had a higher UC risk compared to those who had no variant genotype or the group with the lower levels of cumulative exposure of cigarette smoking and total arsenic concentration, InAs%, and MMA% and highest level group of DMA%. The similar patterns were also observed in subjects carrying the p21 Arg/Arg genotype or carrying the CCND1 GA or AA genotype. Here, we did not observe a significant combination of effects for the three gene polymorphisms and urinary 8-OHdG levels on UC risk. The gene– gene interaction and gene–gene-environment interaction are shown in Table 3. Individuals with the p53 Arg/Arg genotype, p21 Ser/Ser or Ser/Arg genotype or CCND1 GG genotype were used as reference values and individuals with one to three gene variants were compared with the respective reference group. We evaluated simultaneously the three gene variants on the UC risk and combined the effects of urinary arsenic species percentage, 8OHdG levels and cumulative exposure of cigarette smoking. There were significant dose–response relationships among those subjects carrying greater numbers of gene variants and with higher environmental exposure on UC risk, these including cumulative exposure of cigarette smoking, total arsenic concentration, and MMA% (trend p value b 0.05). Furthermore, those with a lower DMA% and

Table 1 Age, gender, urinary 8-OHdG levels and cell cycle regulatory gene polymorphisms of UC cases and healthy controls

Age (years) (Mean ± SE) Gender Male Female 8-OHdG (ng/mg creatinine) (Mean ± SE) b 3.81 3.81–6.52 ≥ 6.52 P53 codon 72 Arg/Arg Arg/Pro Pro/Pro P21 codon 31 Ser/Ser Ser/Arg Arg/Arg Ser/Ser + Ser/Arg Arg/Arg CCND1 G870A GG GA AA SE: standard error.

UC cases (n = 170)

Control (n = 402)

62.14 ± 1.08

61.50 ± 0.71

Age and genderadjusted OR (95% CI)

p value

1.00 (0.99–1.02)

0.65

0.46

123 (72.35) 47 (27.65) 7.48 ± 0.97

277 (68.91) 125 (31.09) 5.95 ± 0.21

1.16 (0.78–1.73) 1.00 2.19 (1.16–4.13)

0.02

56 (32.94) 51 (30.00) 63 (37.06)

134 (33.33) 134 (33.33) 134 (33.33)

1.00 0.96 (0.61–1.51) 1.19 (0.76–1.87)

0.85 0.44

47 (27.65) 87 (51.18) 36 (21.18)

134 (33.33) 194 (48.26) 74 (18.41)

1.00 1.28 (0.84–1.96) 1.42 (0.85–2.40)

0.25 0.18

(26.04) (43.79) (30.18) (69.82) (30.18)

97 (24.13) 216 (53.73) 89 (22.14) 313 (77.86) 89 (22.14)

1.00 0.74 (0.47–1.15) 1.25 (0.76–2.05) 1.00 1.53 (1.02–2.29)

34 (20.00) 84 (49.41) 52 (30.59)

89 (22.14) 200 (49.75) 113 (28.11)

1.00 1.08 (0.68–1.74) 1.17 (0.70–1.96)

44 74 51 118 51

0.18 0.39 0.04

0.74 0.54

206

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209

Table 2 Odds ratios (ORs) for the interaction of smoking, urinary arsenic profiles, 8-OHdG levels and cell cycle regulatory gene polymorphisms in relation to UC risk

Table 2 (continued) CCND1 G870A GG (n = 123)

P53 codon 72

UC/control no.

Arg/Arg (n = 181)

Arg/Pro + Pro/Pro (n = 281)

UC/Control no.

UC/Control no.

OR (95% CI)

Cumulative exposure of cigarette smoking (pack-years)a =0 19/81 1.00 59/174 0–25 9/19 1.46 (0.48–4.42) 23/47 ≥25 15/30 1.62 (0.64–4.11) 34/36 Total arsenic (μg/g creatinine)b b12.15 5/44 12.15–22.10 10/53 ≥22.10 32/37

1.00 1.72 (0.53–5.62) 7.67 (2.57–22.91)

InAs%b b2.86 2.86–6.03 ≥6.03

13/45 11/44 23/45

1.00 0.72 (0.27–1.89) 1.52 (0.65–3.53)

MMA% b b3.29 3.29–9.08 ≥9.08

15/39 4/41 28/54

DMA%c ≥91.46 83.23–91.46 b83.23

12/34 9/44 26/56

8-OHdG (ng/mg creatinine)c b3.81 14/42 3.81–6.52 11/52 ≥6.52 22/40

1.00 0.28 (0.08–0.97) 1.08 (0.48–2.37)

1.00 0.63 (0.22–1.84) 1.48 (0.60–3.67)

1.00 0.82 (0.31–2.14) 1.26 (0.51–3.10)

8/90 26/81 89/97

31/89 41/90 51/89

18/95 31/93 74/80

22/100 38/90 63/78

42/92 40/82 41/94

OR (95% CI)

1.16 (0.61–2.22) 1.36 (0.60–3.08) 3.04 (1.34–6.88) p for trend: b0.01 0.67 (0.19–2.40) 3.03 (1.04–8.84) 8.06 (2.89–22.54) p for trend: b0.01 1.04 (0.48–2.27) 1.46 (0.68–3.12) 1.63 (0.77–3.44) p for trend: 0.04 0.52 (0.23–1.18) 0.66 (0.31–1.43) 2.12 (1.03–4.35) p for trend: b0.01 0.58 (0.24–1.39) 1.13 (0.49–2.62) 2.26 (0.99–5.14)⁎ p for trend: b0.01 1.16 (0.53–2.55) 1.41 (0.51–3.10) 1.07 (0.48–2.37) p for trend: 0.82

P21 codon 31 Ser/Ser + Ser/Arg (n = 141)

Arg/Arg (n = 290)

UC/control no.

UC/control no.

OR (95% CI)

Cumulative exposure of cigarette smoking (pack-years)a =0 56/200 1.00 21/55 0–25 22/51 1.29 (0.62–2.68) 10/15 ≥25 31/52 1.90 (0.94–3.87)# 18/14

OR (95% CI)

1.48 (0.76–2.90) 1.86 (0.67–5.13) 4.51 (1.80–11.33) p for trend: 0.01

Total arsenic (μg/g creatinine)b b12.15 8/107 12.15–22.10 23/100 ≥22.10 87/106

1.00 3.47 (1.39–8.71) 11.53 (4.87–27.31)

5/27 13/34 33/28

2.44 (0.65–9.17) 5.60 (2.00–27.31) 16.10 (6.00–43.18) p for trend: b0.01

InAs%b b2.86 2.86–6.03 ≥6.03

34/101 39/110 45/102

1.00 1.00 (0.56–1.78) 1.28 (0.73–2.25)

10/33 13/24 28/32

0.92 (0.40–2.15) 1.90 (0.83–4.36) 2.23 (1.10–4.49) p for trend: 0.03

MMA%b b3.29 3.29–9.08 ≥9.08

20/105 28/106 70/102

1.00 1.12 (0.58–2.18) 2.94 (1.61–5.36)

13/29 7/28 31/32

2.32 (0.98–5.48)⁎ 0.96 (0.34–2.73) 4.11 (1.99–8.49) p for trend: b0.01

DMA%c ≥91.46 83.23–91.46 b83.23

25/104 36/108 57/101

1.00 1.48 (0.78–2.82) 2.62 (1.42–4.84)

9/30 11/26 31/33

1.33 (0.51–3.47) 1.77 (0.69–4.54) 4.49 (2.11–9.58) p for trend: b0.01

1.00 1.25 (0.68–2.29) 1.16 (0.64–2.11)

20/31 14/28 17/30

2.05 (0.93–4.52)⁎ 1.71 (0.73–4.01) 1.55 (0.69–3.50) p for trend: 0.58

8-OHdG (ng/mg creatinine)c b3.81 35/103 3.81–6.52 37/106 ≥6.52 46/104

GA + AA (n = 284) OR (95% CI)

UC/control no.

Cumulative exposure of cigarette smoking (pack-years)a =0 20/58 1.00 58/197 0–25 4/12 0.76 (0.20–2.99) 28/54 ≥ 25 8/13 1.50 (0.47–4.86) 41/53

OR (95% CI)

0.89 (0.47–1.71) 1.25 (0.56–2.79) 2.13 (0.97–4.70)⁎ p for trend: 0.01

Total arsenic (μg/g creatinine)b b 12.15 1/23 12.15–22.10 8/34 ≥ 22.10 25/32

1.00 4.67 (0.53–41.41) 16.53 (2.01–136.12)

12/111 28/100 96/102

1.91 (0.23–16.01) 5.84 (0.73–46.60)⁎ 17.73 (2.24–140.10) p for trend: b0.01

InAs%b b 2.86 2.86–6.03 ≥ 6.03

10/27 7/33 17/29

1.00 0.60 (0.19–1.88) 1.52 (0.57–4.11)

34/107 45/101 57/105

0.80 (0.34–1.88) 1.10 (0.47–2.58) 1.24 (0.54–2.88) p for trend: 0.08

MMA%b b 3.29 3.29–9.08 ≥ 9.08

10/31 5/34 19/24

1.00 0.36 (0.11–1.23) 2.04 (0.76–5.48)

23/103 30/100 83/110

0.63 (0.26–1.54) 0.69 (0.29–1.65) 1.74 (0.76–3.97) p for trend: b0.01

DMA%c ≥ 91.46 83.23–91.46 b 83.23

8/33 9/27 18/29

1.00 1.44 (0.45–4.64) 2.35 (0.81–6.82)

26/101 38/107 72/105

1.04 (0.40–2.67) 1.48 (0.58–3.76) 3.17 (1.28–7.86) p for trend: b0.01

1.00 2.28 (0.72–7.16) 1.85 (0.60–5.75)

49/101 39/106 48/106

2.10 (0.81–5.50) 1.89 (0.72–4.98) 1.83 (0.70–4.78) p for trend: 0.85

8-OHdG (ng/mg creatinine)c b3.81 7/33 3.81–6.52 12/28 ≥6.52 15/28

a Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, total arsenic and pesticide usage. b Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, smoking and pesticide usage. c Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, smoking, total arsenic and pesticide usage. ⁎ 0.05 b p b 0.1 compared to the reference group.

with greater gene variants had an increased UC risk (trend p value b 0.05). Discussion In 2007, we firstly showed that people from low inorganic arsenic exposure area had still increased UC risk, if they had higher MMA% or lower DMA%. And smoking was highlighted to modify inorganic arsenic-induced UC risk (Pu et al., 2007). In previous paper, we excluded the effects of other UC-associated risk factors and even the influences of nutrient factors. Sequentially, we derived that low inorganic arsenic-induced UC risk might be through high oxidative stress from the results of latest paper (Chung et al., 2008). However, under considering about possible factors of effecting urinary 8-OHdG levels, low inorganic arsenic seemed to be more important than smoking for inducing urinary 8-OHdG levels. In the present study, we further explored if increased UC risk was through disturbing cell cycle regulation of low inorganic arsenic-associated oxidative DNA damage. To our knowledge, this study is the first to simultaneously evaluate the impact of p53, p21 and CCND1 cell cycle regulatory gene polymorphisms on the susceptibility to inorganic arsenic-related UC risk. A significant association between p21 polymorphism and UC risk (Table 1), after adjustment for age and gender (OR = 1.53; 95% CI, 1.02– 2.29), was clearly observable. Also individuals harboring a greater number of cell cycle regulatory gene variants had a significantly increased risk of UC, when they also had a higher cumulative exposure of cigarette smoking, total arsenic concentration, InAs%, MMA% and decreased DMA% than those with lower levels of these variables.

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209 Table 3 Gene–gene interactions and Gene–gene-environmental interactions for UC risk All UC/control no. ORa (95% CI) No variant One variant Two variants Three variants

9/22 40/131 92/208 28/41

Smkpy = 0 (n = 332)

Smkpy N 0 (n = 213)

UC/control no. ORb (95% CI)

UC/control no. ORb (95% CI)

No variant 4/14 One variant 24/80 Two variants 35/137 Three variants 14/24

No variant One variant Two variants Three variants

1.00 0.79 (0.21–2.93) 0.60 (0.17–2.15) 1.85 (0.44–7.72)

3/7 15/46 50/64 13/15

0.80 (0.12–5.41) 0.72 (0.18–2.87) 1.66 (0.46–5.94) 1.95 (0.45–8.46) p for trend: 0.01

Total arsenic concentration (μg/g creatinine) b 16.6 (n = 231)

Total arsenic concentration (μg/g creatinine) ≥ 16.6 (n = 340)

UC/control no. ORc (95% CI)

UC/control no. ORc (95% CI)

1/12 10/59 15/107 4/23

8/10 30/72 77/101 24/18

1.00 1.95 (0.22–17.38) 1.56 (0.18–13.40) 1.81 (0.16–20.20)

10.07 (1.02–99.54) 4.21 (0.50–35.28) 7.52 (0.91–61.87) ⁎ 13.37 (1.50–118.76) p for trend: b 0.01

InAs% b 4.32 (n = 274)

InAs% ≥ 4.32 (n = 297)

UC/control no. ORc (95% CI)

UC/control no. ORc (95% CI)

No variant 4/12 One variant 15/70 Two variants 41/100 Three variants 13/19

1.00 0.59 (0.16–2.22) 1.04 (0.30–3.65) 2.06 (0.51–8.39)

5/10 25/61 51/108 15/22

1.72 (0.34–8.82) 1.00 (0.28–3.66) 1.17 (0.34–4.09) 1.49 (0.37–6.05) p for trend: 0.12

MMA% b 6.10 (n = 247)

MMA% ≥ 6.10 (n = 324)

UC/control no. ORc (95% CI)

UC/control no. ORc (95% CI)

No variant 5/10 One variant 11/61 Two variants 23/106 Three variants 7/24

1.00 0.31 (0.08–1.15)⁎ 0.36 (0.10–1.23) 0.39 (0.09–1.70)

4/12 29/70 69/102 21/17

0.58 (0.11–3.06) 0.58 (0.17–1.99) 1.93 (0.28–3.03) 1.90 (0.50–7.22) p for trend: b 0.01

DMA% ≥ 88 (n = 243)

DMA% b 88 (n = 328)

UC/control no. ORc (95% CI)

UC/control no. ORc (95% CI)

No variant 5/10 One variant 6/64 Two variants 24/108 Three variants 7/19

No variant One variant Two variants Three variants

UC/control no. ORa (95% CI)

1.00 0.67 (0.26–1.72) 0.89 (0.36–2.19) 1.60 (0.58–4.45) p for trend: 0.07

1.00 0.19 (0.05–0.79) 0.41 (0.12–1.40) 0.66 (0.15–2.86)

4/12 34/67 68/100 21/22

0.82 (0.16–4.25) 0.86 (0.25–2.95) 1.16 (0.35–3.82) 1.68 (0.45–6.25) p for trend: b 0.01

8-OHdG (ng/mg creatinine) b 5.20 (n = 285)

8-OHdG (ng/mg creatinine) ≥ 5.20 (n = 286)

UC/control no. ORa (95% CI)

UC/control no. ORa (95% CI)

2/14 16/68 51/101 15/18

1.00 7/8 1.23 (0.24–6.41) 24/63 2.41 (0.49–11.94) 41/107 4.28 (0.74–24.76) 13/23

3.59 (0.52–24.67) 1.67 (0.32–8.73) 1.52 (0.30–7.57) 2.84 (0.50–15.97) p for trend: 0.95

a Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, smoking, total arsenic and pesticide usage. b Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, urinary arsenic concentrations and pesticide usage. c Multivariate ORs were adjusted for age, gender, education, paternal and maternal ethnicity, total arsenic and pesticide usage. ⁎ 0.05 b p b 0.1 compared to the reference group.

Previous associations among the p53 codon72, CCND1 G870A polymorphisms and cancer risk have been reported for esophageal, lung and cervical cancers as well as sporadic adenoma (Jain et al.,

207

2007; Lee et al., 2006; Lewis et al., 2003; Settheetham-Ishida et al., 2004; Zhang et al., 2006). However, our results indicate that p53 codon72 and CCND1 G870A polymorphisms are not associated with UC risk, which is in agreement with previous studies of bladder cancer for p53 codon72 polymorphism (Chen et al., 2004; Toruner et al., 2001), as well as with other studies on bladder cancer and esophageal squamous cell carcinoma for CCND1 G870A polymorphism (Cortessis et al., 2003; Yu et al., 2003). For each of cell cycle regulatory gene polymorphism, we found that the genotype distributions all met Hardy–Weinberg equilibrium conditions. The diverse results may be due to the difference in ethnic background leading to a variation in the allele frequency. The allele frequencies shown in the present study are more or less similar to those reported in northern and southern Taiwan (Huang et al., 2004; Wong et al., 2003; Wu et al., 2003). Our findings suggest that p53 codon 72 and CCND1 G870A polymorphisms may not influence the development of UC. p21 is a cyclin-dependent kinase inhibitor resulting in cell-cycle arrest by inhibiting the G1 to S phase stage (Maddika et al., 2007) and is upregulated by wild-type tumor suppressor protein p53 in cell cycle. A transfection study in with human bladder cancer cells has shown that elevated p21 levels by adenoviral infection may be a potent growth suppressor, especially in the WH cell line (Hall et al., 2000). Also, altered p21 expression, affecting the activity of CDKs, was observed among different cancers. Several immunohistochemical studies have shown the expression of p21 to be related to the clinical outcome and progression of cancers. In 2000, the study showed that p21 over-expression was observed in about 52% of 60 patients with UC while only 39% of the tumors had a functional p53 loss (Ozdemir et al., 2000). It was pointed out that p21 expression was regulated by both p53-dependent and independent pathways, which is in agreement with the in vivo study of Makri et al. (1998) (Makri et al., 1998). Xie et al. (2004) indicated that a loss of p21 expression and a mutation of p53 were related to carcinogenesis in gastric carcinoma. They also showed that a loss of p21 expression is related to the TNM stage (Tumor-Nodes-Metastases) and invasion depth (Xie et al., 2004). Zlotta et al. (1999) revealed that a p21 overexpression positively correlated with p53 and was observed in 23 of 47 patients with superficial bladder tumors and that it was associated with shorter recurrence-free survival. These alternations of p21 expression might interrupt the cell cycle and be inducing apoptosis (Zlotta et al., 1999). The p21 gene is localized at chromosome 6p21.2 and the most abundant p21 polymorphism is located at codon 31, which involves a base change from AGC to AGA and amino acid changes from Ser to Arg (el-Deiry et al., 1993; Koopmann et al., 1995; Xiong et al., 1993). This polymorphism, within the DNA-binding zinc finger motif, might encode functionally distinct proteins resulting in an increasing susceptibility for cancer (Chedid et al., 1994; Huppi et al., 1994). Previous studies have demonstrated people carrying p21 Arg/Arg genotype had increased risk of prostate, bladder and esophageal cancers (Huang et al., 2004; Chen et al., 2002a; Wu et al., 2003). However, Hsieh et al. (2001) reported no association between p21 codon 31 polymorphism and endometriosis in pre-menopausal Taiwanese women (Hsieh et al., 2001). In a case-controlled study of a small subset of 140 Caucasians, with primary open angle glaucoma (POAG) and 73 healthy individuals, the results showed that p21 codon 31 polymorphism did not contribute to the risk of POAG (Ressiniotis et al., 2005). In the present study, men carried a greater frequency of the p21 Arg/Arg genotype than women. Also after adjusting for age and gender, subjects with the Arg/Arg genotype had a 1.53-fold increased risk of developing UC, compared with those with Ser/Ser or Ser/Arg genotypes. Further study would be warranted in order to clarify the functional effects of p21 codon 31 polymorphisms and to explore the importance of other polymorphic sites in p21 (Bahl et al., 2000; Ralhan et al., 2000) on UC risk.

208

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209

The induction of p21 results in CDK inhibition and cell cycle arrest as well as preventing the replication of damaged DNA (Ko and Prives, 1996). Although the correlation between enzyme activity and genotype is unclear, our data shows that subjects with the p21 Arg/ Arg variant genotype had increasing UC risks with increasing cumulative exposure of cigarette smoking, total arsenic concentration, InAs%, MMA% and decreasing DMA%. In addition, the significant dose–response relationship of the occurrence of inorganic arsenicrelated UC risk is due to hereditary differences in cell cycle regulatory genes, including p53 and CCND1 polymorphisms. Although inorganic arsenic toxicity has been suggested to be dependent on the species of arsenic and various mechanisms have been proposed to explain its effects, a postulated mechanism of toxicity for could be through oxidative stress (Cohen et al., 2007). Oxidative DNA damage, induced by environmental and endogenous processes, is repaired through efficient DNA repair mechanisms, as well as through cell cycle control, to maintain DNA integrity (Hartwig et al., 2002). Impairment of these protective repair mechanisms by inorganic arsenic exposure may lead to an increased risk of cancer (Chanda et al., 2006; Hamadeh et al., 1999; Kelsey et al., 2005; Moore et al., 2003). Experimental studies of a sodium arsenite-treated HT1197 bladder cell line have showed that arsenite treatment (1–10 μM) for 24 h induced a dose-dependent increase in the proportion of cells in the S-phase. The change in Sphase was accompanied by an increase in p53 protein content and a transient increase in p21 protein levels under the time-course of arsenite effects (10 μM). This suggests that p21 is not able to block the activity of the CDK2-cyclin E complex and is unable to arrest cells in G1 and allowing progression to the S-phase (Hernandez-Zavala et al., 2005). Previously, we demonstrated that oxidative damage as urinary 8-OHdG levels, was associated with urinary arsenic profile at low arsenic exposure (Chung et al., 2008). Also UC cases with higher urinary 8-OHdG levels had a 2.19-fold increased risk, compared with healthily controls, after adjusting age and gender. In the present study, subjects carrying the variant genotype of cell cycle genes exposed to high total arsenic concentrations or possessing higher MMA% and/or lower DMA% may lead to a dose–response increased risk of UC. However, we did not find an interaction of 8-OHdG levels (or cumulative exposure tobacco smoking) with cell cycle gene polymorphisms with respect to UC risk. In addition to the regulation of cell cycle progression, one other response to DNA damage is the DNA-repair process (Hartwig et al., 2002). This suggests that inorganic arsenic could directly regulate cell cycle progression for increased UC risk and inorganic arsenic-induced oxidative damage might be repaired through other DNA mechanisms. Hence, in future studies we plan to evaluate the role of DNA-repair related gene polymorphisms and inorganic arsenic methylation capability on the UC risk. Several limitations in the present study were to be considered. One is that UC cases were prevalent cases and we didn’t know if they had changed their dietary habits or medication states at recruitment. In addition, we didn’t obtain any information of food consumption from questionnaire. Although some seafood intake or medication states might alter the levels of urinary total arsenic concentration and 8-OHdG, the bias should be minimized. We collected the specimens of UC cases before they received any clinical treatment to avoid the effects of medication states. In addition, we analyzed urinary arsenic profile of 36 men and 42 women before and after refraining from eating seafood for 3 days (Hsueh et al., 2002). The data showed that urinary arsenic profile was not changed with the frequencies of fish, shellfish and seaweed intake. Nevertheless, we could not rule out other possibility to alter the levels of urinary total arsenic concentration and 8-OHdG including vitamins supplement. In summary, our study shows that a variant genotype of p21 might be a predictor of low inorganic arsenic-related UC risk. Moreover, a combination of cell cycle gene polymorphisms with

inorganic arsenic methylation capability (or cumulative exposure cigarette smoking) significantly modifies the UC risk. The effect of urinary 8-OHdG levels on cell cycle gene polymorhisms for UC risk under low arsenic exposure seemed not the only way for inorganic arsenic carcinogenesis. Acknowledgments The study was supported by grants from the National Science Council of the ROC (NSC91-3112-B-038-0019, NSC92-3112-B-038-001, NSC93-3112-B-038-001, NSC94-2314-B-038-023, NSC-95-2314-B038-007, and NSC- 96-2314-B-038-003). References Ara, S., Lee, P.S., Hansen, M.F., Saya, H., 1990. Codon 72 polymorphism of the TP53 gene. Nucleic. Acids. Res. 18, 4961. Bahl, R., Arora, S., Nath, N., Mathur, M., Shukla, N.K., Ralhan, R., 2000. Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 19, 323–328. Bates, M.N., Smith, A.H., Hopenhayn-Rich, C., 1992. Arsenic ingestion and internal cancers: a review. Am. J. Epidemiol. 135, 462–476. Betticher, D.C., Thatcher, N., Altermatt, H.J., Hoban, P., Ryder, W.D., Heighway, J., 1995. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005–1011. Cai, K., Dynlacht, B.D., 1998. Activity and nature of p21(WAF1) complexes during the cell cycle. Proc. Natl. Acad. Sci. U.S.A 95, 12254–12259. Ceschi, M., Sun, C.L., Van Den, B.D., Koh, W.P., Yu, M.C., Probst-Hensch, N., 2005. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26, 1457–1464. Chanda, S., Dasgupta, U.B., Guhamazumder, D., Gupta, M., Chaudhuri, U., Lahiri, S., Das, S., Ghosh, N., Chatterjee, D., 2006. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol. Sci. 89, 431–437. Chedid, M., Michieli, P., Lengel, C., Huppi, K., Givol, D., 1994. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9, 3021–3024. Chen, W.C., Wu, H.C., Hsu, C.D., Chen, H.Y., Tsai, F.J., 2002a. p21 gene codon 31 polymorphism is associated with bladder cancer. Urol. Oncol. 7, 63–66. Chen, Y.C., Amarasiriwardena, C.J., Hsueh, Y.M., Christiani, D.C., 2002b. Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol. Biomarkers Prev. 11, 1427–1433. Chen, Y.C., Xu, L., Guo, Y.L., Su, H.J., Smith, T.J., Ryan, L.M., Lee, M.S., Christiani, D.C., 2004. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in southwestern Taiwan: a preliminary study. Biomarkers 9, 386–394. Chung, C.J., Huang, C.J., Pu, Y.S., Su, C.T., Huang, Y.K., Chen, Y.T., Hsueh, Y.M., 2008. Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. Toxicol. Appl. Pharmacol. 226, 14–21. Cohen, S.M., Ohnishi, T., Arnold, L.L., Le, X.C., 2007. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol. 222, 258–263. Cortessis, V.K., Siegmund, K., Xue, S., Ross, R.K., Yu, M.C., 2003. A case-control study of cyclin D1 CCND1 870A–NG polymorphism and bladder cancer. Carcinogenesis 24, 1645–1650. De, C.S., Mahata, J., Das, J.K., Mukherjee, A., Ghosh, P., Sau, T.J., Mondal, L., Basu, S., Giri, A.K., Roychoudhury, S., 2006. Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 601, 102–112. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein, B., 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825. Furihata, M., Takeuchi, T., Matsumoto, M., Kurabayashi, A., Ohtsuki, Y., Terao, N., Kuwahara, M., Shuin, T., 2002. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res. 8, 1192–1195. Gonsebatt, M.E., Vega, L., Herrera, L.A., Montero, R., Rojas, E., Cebrian, M.E., OstroskyWegman, P., 1992. Inorganic arsenic effects on human lymphocyte stimulation and proliferation. Mutat. Res. 283, 91–95. Gumerlock, P.H., Chi, S.G., Shi, X.B., Voeller, H.J., Jacobson, J.W., Gelmann, E.P., Vere White, R.W., 1997. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. JNCI Journal of the National Cancer Institute 89, 66–71. Hall, M.C., Li, Y., Pong, R.C., Ely, B., Sagalowsky, A.I., Hsieh, J.T., 2000. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J. Urol. 163, 1033–1038. Hamadeh, H.K., Vargas, M., Lee, E., Menzel, D.B., 1999. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem. Biophys. Res. Commun. 263, 446–449. Hartwig, A., Asmuss, M., Ehleben, I., Herzer, U., Kostelac, D., Pelzer, A., Schwerdtle, T., Burkle, A., 2002. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ. Health. Perspect. 110 (Suppl 5), 797–799.

C.-J. Chung et al. / Toxicology and Applied Pharmacology 232 (2008) 203–209 Hartwig, A., Blessing, H., Schwerdtle, T., Walter, I., 2003. Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology 193, 161–169. Hernandez-Zavala, A., Cordova, E., Del Razo, L.M., Cebrian, M.E., Garrido, E., 2005. Effects of arsenite on cell cycle progression in a human bladder cancer cell line. Toxicology 207, 49–57. Hsieh, Y.Y., Tsai, F.J., Chang, C.C., Chen, W.C., Tsai, C.H., Tsai, H.D., Lin, C.C., 2001. p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis. J. Clin. Lab. Anal. 15, 184–187. Hsueh, Y.M., Huang, Y.L., Huang, C.C., Wu, W.L., Chen, H.M., Yang, M.H., Lue, L.C., Chen, C.J., 1998. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J. Toxicol. Environ. Health 54, 431–444. Hsueh, Y.M., Hsu, M.K., Chiou, H.Y., Yang, M.H., Huang, C.C., Chen, C.J., 2002. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol. Lett. 133, 83–91. Huang, S.P., Wu, W.J., Chang, W.S., Wu, M.T., Chen, Y.Y., Chen, Y.J., Yu, C.C., Wu, T.T., Lee, Y.H., Huang, J.K., Huang, C.H., 2004. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13, 2217–2224. Huppi, K., Siwarski, D., Dosik, J., Michieli, P., Chedid, M., Reed, S., Mock, B., Givol, D., Mushinski, J.F., 1994. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 9, 3017–3020. Izzo, J.G., Papadimitrakopoulou, V.A., Liu, D.D., den Hollander, P.L., Babenko, I.M., Keck, J., El-Naggar, A.K., Shin, D.M., Lee, J.J., Hong, W.K., Hittelman, W.N., 2003. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. JNCI Journal of the National Cancer Institute 95, 198–205. Jain, M., Kumar, S., Lal, P., Tiwari, A., Ghoshal, U.C., Mittal, B., 2007. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect. Prev. 31, 225–232. Kelsey, K.T., Hirao, T., Hirao, S., vi-Ashok, T., Nelson, H.H., Andrew, A., Colt, J., Baris, D., Morris, J.S., Schned, A., Karagas, M., 2005. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int. J. Cancer 117, 370–375. Keshava, C., Frye, B.L., Wolff, M.S., McCanlies, E.C., Weston, A., 2002. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol. Biomarkers Prev. 11, 127–130. Kitchin, K.T., 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172, 249–261. Ko, L.J., Prives, C., 1996. p53: puzzle and paradigm. Genes Dev. 10, 1054–1072. Koopmann, J., Maintz, D., Schild, S., Schramm, J., Louis, D.N., Wiestler, O.D., von, D.A., 1995. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br. J. Cancer 72, 1230–1233. Kuroda, Y., Tsukino, H., Nakao, H., Imai, H., Katoh, T., 2003. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 189, 77–83. Le, M.L., Seifried, A., Lum-Jones, A., Donlon, T., Wilkens, L.R., 2003. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA: The Journal of the American Medical Association 290, 2843–2848. Lee, J.M., Shun, C.T., Wu, M.T., Chen, Y.Y., Yang, S.Y., Hung, H.I., Chen, J.S., Hsu, H.H., Huang, P.M., Kuo, S.W., Lee, Y.C., 2006. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594, 181–188. Lewis, R.C., Bostick, R.M., Xie, D., Deng, Z., Wargovich, M.J., Fina, M.F., Roufail, W.M., Geisinger, K.R., 2003. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res. 63, 8549–8553. Li, Y.J., Laurent-Puig, P., Salmon, R.J., Thomas, G., Hamelin, R.,1995. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10, 599–601. Maddika, S., Ande, S.R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K.D., Wiechec, E., Los, M., 2007. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13–29. Makri, D., Schulz, W.A., Grimm, M., Clasen, S., Bojar, H., Schmitz-Drager, B.J., 1998. WAF1/ p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int. J. Oncol. 12, 621–628. Moore, L.E., Smith, A.H., Eng, C., DeVries, S., Kalman, D., Bhargava, V., Chew, K., Ferreccio, C., Rey, O.A., Hopenhayn, C., Biggs, M.L., Bates, M.N., Waldman, F.M., 2003. P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 24, 1785–1791. Mousses, S., Ozcelik, H., Lee, P.D., Malkin, D., Bull, S.B., Andrulis, I.L., 1995. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet. 4, 1089–1092. Ozdemir, E., Kakehi, Y., Yoshida, O., 2000. p21(WAF-1/CIP-1), a downstream regulator of functional p53 loss, in transitional cell carcinoma of urothelium. Eur. Urol. 38, 230–234.

209

Papadakis, E.N., Dokianakis, D.N., Spandidos, D.A., 2000. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 3, 389–392. Pilger, A., Ivancsits, S., Germadnik, D., Riger, H.W., 2002. Urinary excretion of 8-hydroxy2'-deoxyguanosine measured by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 778, 393–401. Pu, Y.S., Yang, S.M., Huang, Y.K., Chung, C.J., Huang, S.K., Chiu, A.W., Yang, M.H., Chen, C.J., Hsueh, Y.M., 2007. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol. Appl. Pharmacol. 218, 99–106. Ralhan, R., Agarwal, S., Mathur, M., Wasylyk, B., Srivastava, A., 2000. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin. Cancer Res. 6, 2440–2447. Ressiniotis, T., Griffiths, P.G., Keers, S.M., Chinnery, P.F., Birch, M., 2005. A polymorphism at codon 31 of gene p21 is not associated with primary open angle glaucoma in Caucasians. BMC. Ophthalmol. 5, 5. Roh, J., Kim, M., Kim, J., Park, N., Song, Y., Kang, S., Lee, H., 2001. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 165, 59–62. Settheetham-Ishida, W., Singto, Y., Yuenyao, P., Tassaneeyakul, W., Kanjanavirojkul, N., Ishida, T., 2004. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett. 210, 205–211. Sjalander, A., Birgander, R., Hallmans, G., Cajander, S., Lenner, P., Athlin, L., Beckman, G., Beckman, L., 1996. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17, 1313–1316. Soulitzis, N., Sourvinos, G., Dokianakis, D.N., Spandidos, D.A., 2002. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179, 175–183. Su, L., Liu, G., Zhou, W., Xu, L.L., Miller, D.P., Park, S., Lynch, T.J., Wain, J.C., Christiani, D.C., 2003. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 12, 174–175. Sun, Y., Hildesheim, A., Li, H., Li, Y., Chen, J.Y., Cheng, Y.J., Hayes, R.B., Rothman, N., Bi, W.F., Cao, Y., 1995. No point mutation but a codon 31ser–Narg polymorphism of the WAF1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol. Biomarkers Prev. 4, 261–267. Sun, Y., Keshava, C., Sharp, D.S., Weston, A., McCanlies, E.C., 1999. DNA sequence variants of p53: cancer and aging. Am. J. Hum. Genet. 65, 1779–1782. Tapio, S., Grosche, B., 2006. Arsenic in the aetiology of cancer. Mutat. Res. 612, 215–246. Toruner, G.A., Ucar, A., Tez, M., Cetinkaya, M., Ozen, H., Ozcelik, T., 2001. P53 codon 72 polymorphism in bladder cancer–no evidence of association with increased risk or invasiveness. Urol. Res. 29, 393–395. Tsai, M.H., Chen, W.C., Tsai, F.J., 2002. Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma. J. Clin. Lab. Anal. 16, 146–150. Wong, Y.K., Lin, S.C., Chang, C.S., Tseng, Y.H., Liu, C.J., Lin, H.C., Chang, K.W., 2003. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J. Oral Pathol. Med. 32, 265–270. Wu, M.T., Wu, D.C., Hsu, H.K., Kao, E.L., Yang, C.H., Lee, J.M., 2003. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett. 201, 175–180. Xie, H.L., Su, Q., He, X.S., Liang, X.Q., Zhou, J.G., Song, Y., Li, Y.Q., 2004. Expression of p21 (WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J. Gastroenterol. 10, 1125–1131. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., Beach, D., 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701–704. Yoshida, T., Yamauchi, H., Fan, S.G., 2004. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198, 243–252. Yu, C., Lu, W., Tan, W., Xing, D., Liang, G., Miao, X., Lin, D., 2003. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 12, 176. Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., Lin, D., 2006. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27, 110–117. Zlotta, A.R., Noel, J.C., Fayt, I., Drowart, A., Van Vooren, J.P., Huygen, K., Simon, J., Schulman, C.C., 1999. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J. Urol. 161, 792–798.